Leidi.com Lei Jianping September 13
Shanghai Yinuosi Biotechnology Co., Ltd. (referred to as "Yinuosi") recently passed its IPO and is preparing to be listed on the Science and Technology Innovation Board. Yinuosi plans to raise 1.602 billion yuan.
Among them, 1.045 billion yuan will be used for the Yinuosi headquarters and innovation transformation center project, 357 million yuan will be used for the high-quality non-clinical innovative drug comprehensive evaluation platform expansion project, and 200 million yuan will be used to supplement working capital.
Annual revenue of 860 million, experimental monkeys are core raw materials
Founded in 2010, Yinuosi is a holding subsidiary of China National Pharmaceutical Research Institute Co., Ltd., a subsidiary of Sinopharm Group. It is a professional comprehensive research and development services (CRO) enterprise that mainly provides biomedical non-clinical research services.
Yinuosi's services mainly cover three major areas: early drugability evaluation of biomedicine, non-clinical research, and clinical testing and translational research.
After years of development, Yinuosi currently has nearly 60,000 square meters of modern facilities and a research team of more than a thousand people located in Shanghai, Nantong, Shenzhen and other places.
The prospectus shows that Yinuosi’s revenue in 2020, 2021, and 2022 will be 334 million, 582 million, and 863 million respectively; net profits will be 48.51 million, 92.479 million, and 118 million respectively; net profits after non-deductions will be 30.9988 million yuan, 60.665 million yuan, 107 million yuan.
Experimental monkeys are the main raw material of Yinuosi. During the reporting period, the income generated by the business involving the use of experimental monkeys was 117 million yuan, 260 million yuan and 414 million yuan respectively, accounting for 35.12% and 35.12% of the main business income respectively. 44.77% and 48%.
During the reporting period, the prices of experimental animals represented by experimental monkeys continued to rise, with the purchase price rising from 27,300 yuan/animal in 2020 to 107,800 yuan/animal in 2022, increasing the company's production costs.
Sinopharm is the major shareholder
As of the signing date of this prospectus, Sinopharm Group directly holds 6,223,318 shares of Yinuosi, accounting for 5.8858% of the total share capital of Yinuosi. At the same time, Sinopharm Group holds indirect shares through its wholly-owned subsidiaries, General Medical and Industrial Research Institute and Sinopharm Investment Yinuosi has 39,666,044 shares, accounting for 37.5147% of the total share capital of Yinuosi. It holds a total of 43.4005% of the company's shares. It actually controls more than 30% of the voting rights of the shares and is the actual controller.
Before the IPO, the General Hospital of Medical Industry held 26.6748%, Aopeng Partnership held 16.468%, Zhangjiang Crude Medicine Base held 14.423%, Sinopharm Investment held 10.8399%, Advanced Manufacturing held 6.2669%, and Sinopharm Group held 14.423%. shares are 5.8858%, and public technology holdings are 5.2104%;
Pudong New Industrial Investment holds 4.578%, Shanghai Science and Technology Venture Capital holds 4.4143%, Huazhen Partnership holds 2.9429%, Jingang Biotech holds 0.8829%, Yitian Partnership holds 0.8245%, and Huangshan Cultural Tourism Fund holds The share price is 0.5886%.
After the IPO, the General Hospital of Medical Industry held 20.0061% of the shares, Aopeng Partnership held 12.351% of the shares, Zhangjiang Crude Medicine Base held 10.8173% of the shares, Sinopharm Investment held 8.1299% of the shares, Advanced Manufacturing held 4.7002% of the shares, and Sinopharm Group held shares are 4.4143%, and public technology holdings are 3.9078%;
Pudong Xinchan Investment holds 3.4335%, Shanghai Science and Technology Venture Capital holds 3.3108%, Huazhen Partnership holds 2.2072%, Jingang Biotech holds 0.6622%, Yitian Partnership holds 0.6184%, Huangshan Cultural Tourism Fund holdings are 0.4414%.
———————————————
Leidi was founded by media person Lei Jianping. If you reprint, please indicate the source.
